keyword
MENU ▼
Read by QxMD icon Read
search

cutaneous adverse effects, drug

keyword
https://www.readbyqxmd.com/read/28225974/do-you-know-this-syndrome-hand-foot-syndrome
#1
Cintia Santos Braghiroli, Rodrigo Ieiri, Juliana Polizel Ocanha, Rafael Bispo Paschoalini, Hélio Amante Miot
Hand-foot syndrome is a common cutaneous adverse effect associated with certain systemic chemotherapy drugs. It is characterized by erythema, edema, and burning sensation, especially over palmoplantar surfaces. We report the case of an elderly patient undergoing chemotherapy after a breast cancer surgery who developed symptoms two months after the start of the regimen. There are no studies that explore specific therapies. Suggestive therapy include reducing agent dosage, increasing the interval between cycles, or even stopping chemotherapy...
January 2017: Anais Brasileiros de Dermatologia
https://www.readbyqxmd.com/read/28195065/effect-of-econazole-and-benzydamine-on-sensory-neurons-in-culture
#2
S Mathivanan, R de la Torre-Martinez, C Wolf, G Mangano, L Polenzani, C Milanese, A Ferrer-Montiel
Econazole is an anti-mycotic agent widely used for the treatment of cutaneous fungal infections, and for the therapy of vaginal candidiasis. Topical application of this azole is generally safe, although some patients have complained of mild burning sensation/cutaneous irritation and itching, especially when administered intravaginally. The underlying mechanisms responsible of these adverse effects are poorly understood, though they suggest excitation of cutaneous nociceptor terminals. We report that exposure of primary cultures of rat nociceptors to econazole augments neuronal excitability...
December 2016: Journal of Physiology and Pharmacology: An Official Journal of the Polish Physiological Society
https://www.readbyqxmd.com/read/28190531/cutaneous-adverse-effects-of-the-immune-checkpoint-inhibitors
#3
REVIEW
Lindsey K Collins, M Shane Chapman, Joi B Carter, Faramarz H Samie
The immune checkpoint targeted agents, anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and anti-programed cell death 1 (PD-1) or anti-programmed death ligand 1 (PD-L1) inhibitors are frequently associated with cutaneous side effects that are often dose limiting and can lead to discontinuation of therapy. Ipilimumab, a CTLA-4 inhibitor, is most commonly associated with a morbilliform eruption on the trunk and extremities and pruritus. More severe cutaneous toxicities reported include toxic epidermal necrolysis and severe drug rash with eosinophila and systemic symptoms...
December 14, 2016: Current Problems in Cancer
https://www.readbyqxmd.com/read/28165853/biocompatibility-and-characterization-of-polyglycerol-based-thermoresponsive-nanogels-designed-as-novel-drug-delivery-systems-and-their-intracellular-localization-in-keratinocytes
#4
Christian Gerecke, Alexander Edlich, Michael Giulbudagian, Fabian Schumacher, Nan Zhang, Andre Said, Guy Yealland, Silke B Lohan, Falko Neumann, Martina C Meinke, Nan Ma, Marcelo Calderón, Sarah Hedtrich, Monika Schäfer-Korting, Burkhard Kleuser
Novel nanogels that possess the capacity to change their physico-chemical properties in response to external stimuli are promising drug delivery candidates for the treatment of severe skin diseases. As thermoresponsive nanogels (tNGs) are capable of enhancing penetration through biological barriers such as the stratum corneum and are taken up by keratinocytes of human skin, potential adverse consequences of their exposure must be elucidated. In this study, tNGs were synthesized from dendritic polyglycerol (dPG) and two thermoresponsive polymers...
February 6, 2017: Nanotoxicology
https://www.readbyqxmd.com/read/28164401/skin-depigmentation-associated-with-toceranib-phosphate-in-a-dog
#5
Jacqueline V J Cavalcanti, Andrea Hasbach, Katie Barnes, Rahul B Dange, Jon Patterson, Paulo Vilar Saavedra
BACKGROUND: Drug-induced depigmentation is frequently observed in humans undergoing tyrosine kinase inhibitor therapy, whereas it is not reported in dogs. The skin depigmentation can occur after the first week of treatment and it is reversible within a few weeks after drug discontinuation. OBJECTIVES: To report the clinical and histopathological features of an episode of cutaneous adverse drug reaction associated with short term administration of toceranib phosphate...
February 6, 2017: Veterinary Dermatology
https://www.readbyqxmd.com/read/28162999/health-related-quality-of-life-with-adjuvant-ipilimumab-versus-placebo-after-complete-resection-of-high-risk-stage-iii-melanoma-eortc-18071-secondary-outcomes-of-a-multinational-randomised-double-blind-phase-3-trial
#6
Corneel Coens, Stefan Suciu, Vanna Chiarion-Sileni, Jean-Jacques Grob, Reinhard Dummer, Jedd D Wolchok, Henrik Schmidt, Omid Hamid, Caroline Robert, Paolo A Ascierto, Jon M Richards, Celeste Lebbé, Virginia Ferraresi, Michael Smylie, Jeffrey S Weber, Michele Maio, Andrew Bottomley, Srividya Kotapati, Veerle de Pril, Alessandro Testori, Alexander M M Eggermont
BACKGROUND: The EORTC 18071 phase 3 trial compared adjuvant ipilimumab with placebo in patients with stage III melanoma. The primary endpoint, recurrence-free survival, was significantly longer in the ipilimumab group than in the placebo group. Investigator-reported toxic effects of ipilimumab consisted mainly of skin, gastrointestinal, endocrine, and hepatic immune-related adverse events. Adjuvant treatment with ipilimumab in this setting was approved in October, 2014, by the US Food and Drug Administration based on the results of the primary outcome of this trial...
February 2, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28161548/anti-melasma-codrug-of-retinoic-acid-assists-cutaneous-absorption-with-attenuated-skin-irritation
#7
Pei-Wen Hsieh, Chi-Feng Hung, Chih-Hung Lin, Chang-Wei Huang, Jia-You Fang
Melasma treatment with combined retinoic acid (RA) and hydroquinone (HQ) usually causes unsatisfactory outcomes and safety concerns. This study attempted to evaluate the cutaneous absorption and skin tolerance of the codrug conjugated with RA and HQ via ester linkage. The codrug's permeation of the pig skin was estimated using Franz diffusion cell. The codrug and parent drugs were comparatively examined for anti-inflammatory activity and tyrosinase inhibition. In vivo cutaneous irritation was assessed on nude mouse skin...
February 1, 2017: European Journal of Pharmaceutics and Biopharmaceutics
https://www.readbyqxmd.com/read/28150343/vemurafenib-induced-toxic-epidermal-necrolysis-is-it-an-emerging-side-effect-of-the-drug
#8
S Kılıç, E Özkaya, C Baykal, S Vatansever
Vemurafenib, a selective inhibitor of the BRAF-kinase used in treatment of metastatic melanoma alone or in combinations,(1) is known to cause various adverse skin reactions such as maculopapular rash, photosensitivity and hyperkeratotic lesions, affecting more than 90% of patients.(1-2) Severe adverse reactions were observed in less than 1% of the patients in clinical trials.(3) However, the increasing number of reported cases of vemurafenib-induced toxic epidermal necrolysis (TEN), a life-threatening severe cutaneous adverse reaction, is striking...
February 1, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28118487/electrochemotherapy-in-the-treatment-of-metastatic-malignant-melanoma-a-prospective-cohort-study-by-inspect
#9
C Kunte, V Letulé, J Gehl, K Dahlstroem, P Curatolo, R Rotunno, T Muir, A Occhini, G Bertino, B Powell, W Saxinger, G Lechner, S-H Liew, R Pritchard-Jones, P Rutkowski, M Zdzienicki, D Mowatt, A J Sykes, A Orlando, G Mitsala, C R Rossi, L Campana, M Brizio, F de Terlizzi, P Quaglino, J Odili
BACKGROUND: Electrochemotherapy (ECT) is an effective local treatment for cutaneous metastasis. Treatment involves the administration of chemotherapeutic drugs followed by delivery of electrical pulses to the tumour. The aim of this study was to investigate the effectiveness of ECT in cutaneous metastases of melanoma and to identify factors which affect (beneficially or adversely) the outcome. METHODS: 13 cancer centres in the International Network for Sharing Practices on Electrochemotherapy (INSPECT) consecutively and prospectively uploaded data to a common database...
January 24, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28105242/skin-toxicity-in-a-patient-with-ovarian-cancer-treated-with-pegylated-liposomal-doxorubicin-a-case-report-and-review-of-the-literature
#10
Joanna Kubicka-Wołkowska, Magdalena Kędzierska, Maja Lisik-Habib, Piotr Potemski
Pegylated liposomal doxorubicin (PLD) is a form of doxorubicin enclosed in pegylated liposomes. In contrast to conventional doxorubicin, PLD is characterized by a lower incidence of cardiotoxicity and myelosuppression. However, it induces specific mucocutaneous side effects, particularly palmar-plantar erythrodysesthesia (PPE). Other dermal manifestations, such as intertrigo-like dermatitis, diffuse follicular rash, melanotic macules, maculopapular rash or recall phenomenon are less common. Mechanisms that lead to skin toxicity remain unclear, however, certain reports indicate that drug excretion in sweat, host-vs...
December 2016: Oncology Letters
https://www.readbyqxmd.com/read/28095529/open-label-study-evaluating-the-anti-aging-effects-of-a-3-product-2-step-retinol-rejuvenation-system-following-3-months-of-treatment-in-subjects-with-photodamage
#11
Suzanne Bruce, Sylvia Barkovic
BACKGROUND: Photodamage to the skin occurs with exposure to sunlight (UVA or UVB) either intentionally or unintentionally, and can present in a variety of ways. It typically occurs on areas of chronic UV exposure, including the face, ears, and neck. METHODS: We evaluated the effects of a 3-product, 2-step retinol-rejuvenation system containing an exfoliating cleanser, a 0.5% retinol emollient cream, and SPF 30 moisturizing sunscreen used daily for 3 months on the appearance of mild-to-moderate facial photodamage in female subjects...
January 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28071592/development-and-evaluation-of-zinc-phthalocyanine-nanoemulsions-for-use-in-photodynamic-therapy-for-leishmania-spp
#12
Luciana Betzler de Oliveira de Siqueira, Verônica da Silva Cardoso, Igor Almeida Rodrigues, Ana Lúcia Vazquez-Villa, Elisabete Pereira Dos Santos, Bruno da Costa Leal Ribeiro Guimarães, Cristal Dos Santos Cerqueira Coutinho, Alane Beatriz Vermelho, Eduardo Ricci Junior
Photodynamic therapy (PDT) combines light with photosensitizers (PS) for production of reactive oxygen species (ROS) that can kill infectious microorganisms such as bacteria, fungi and protozoa. The application of nanotechnology has enabled the advancement of PDT because many PS are insoluble in water, necessitating a nanocarrier as a physiologically acceptable carrier. Nanoemulsions are efficient nanocarriers for solubilizing liposoluble drugs, like the PS, in water. Cutaneous (CL) and mucocutaneous leishmaniasis (ML) are caused by different species of the genus Leishmania, transmitted to humans by sandfly bites...
February 10, 2017: Nanotechnology
https://www.readbyqxmd.com/read/28069279/masitinib-for-treatment-of-severely-symptomatic-indolent-systemic-mastocytosis-a-randomised-placebo-controlled-phase-3-study
#13
Olivier Lortholary, Marie Olivia Chandesris, Cristina Bulai Livideanu, Carle Paul, Gérard Guillet, Ewa Jassem, Marek Niedoszytko, Stéphane Barete, Srdan Verstovsek, Clive Grattan, Gandhi Damaj, Danielle Canioni, Sylvie Fraitag, Ludovic Lhermitte, Sophie Georgin Lavialle, Laurent Frenzel, Lawrence B Afrin, Katia Hanssens, Julie Agopian, Raphael Gaillard, Jean-Pierre Kinet, Christian Auclair, Colin Mansfield, Alain Moussy, Patrice Dubreuil, Olivier Hermine
BACKGROUND: Indolent systemic mastocytosis, including the subvariant of smouldering systemic mastocytosis, is a lifelong condition associated with reduced quality of life. Masitinib inhibits KIT and LYN kinases that are involved in indolent systemic mastocytosis pathogenesis. We aimed to assess safety and efficacy of masitinib versus placebo in severely symptomatic patients who were unresponsive to optimal symptomatic treatments. METHODS: In this randomised, double-blind, placebo-controlled, phase 3 study, we enrolled adults (aged 18-75 years) with indolent or smouldering systemic mastocytosis, according to WHO classification or documented mastocytosis based on histological criteria, at 50 centres in 15 countries...
February 11, 2017: Lancet
https://www.readbyqxmd.com/read/28057839/niacin-promotes-cardiac-healing-after-myocardial-infarction-through-activation-of-the-myeloid-prostaglandin-d2-receptor-subtype-1
#14
Deping Kong, Juanjuan Li, Yujun Shen, Guihu Liu, Shengkai Zuo, Bo Tao, Yong Ji, Ankang Lu, Michael Lazarus, Richard M Breyer, Ying Yu
Niacin is a well-established drug used to lower cholesterol and prevent cardiovascular disease (CVD) events. However, niacin also causes cutaneous flushing side effects due to release of the proresolution mediator prostaglandin (PG) D2. Recent randomized clinical trials have demonstrated that addition of niacin with laropiprant (a PGD2 receptor subtype 1 [DP1] blocker) to statin-based therapies does not significantly decrease the risk of CVD events but increases the risk of serious adverse events. Here, we tested whether, and how, niacin beneficial effects in vivo myocardial ischemia requires the activation of the PGD2/DP1 axis...
January 5, 2017: Journal of Pharmacology and Experimental Therapeutics
https://www.readbyqxmd.com/read/27992698/effects-of-hydroxychloroquine-on-cutaneous-lupus-erythematosus-a-multi-center-double-blind-randomized-parallel-group-trial
#15
N Yokogawa, H Eto, A Tanikawa, T Ikeda, K Yamamoto, T Takahashi, H Mizukami, T Sato, N Yokota, F Furukawa
Objectives To assess the efficacy and tolerability of hydroxychloroquine (HCQ) in a phase III clinical trial conducted in Japan Methods A double-blind randomized parallel-group clinical trial was performed. This was a baseline-controlled study and the group differences were evaluated in an exploratory analysis. A total of 103 patients with active CLE (CLASI activity score ≥4) were included. Patients were randomized (3:1) to receive HCQ or placebo in the 16-week double-blind period, and all patients were given HCQ in the following 36-week single-blind period...
December 19, 2016: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/27943305/use-of-skin-lightening-products-among-selected-urban-communities-in-accra-ghana
#16
Margaret Lartey, Francis D Krampa, Mubarak Abdul-Rahman, Naa L Quarcoo, Phaedra Yamson, Paa G Hagan, Yao Tettey, Richard Gyasi, Andrew A Adjei
BACKGROUND: The practice of skin lightening has been reported from North America, Europe, Asia, and Africa. In literature, some prevalence rates exceed 50%, and both sexes are involved. Common agents used include hydroquinone, mercury, corticosteroids, and caustic agents. The agents are easily accessible and affordable with very little regulation. Cutaneous and systemic side effects occur but do not appear to be a deterrent, as the notion of light skin as a surrogate for beauty is strong...
January 2017: International Journal of Dermatology
https://www.readbyqxmd.com/read/27922065/detc-based-bacterial-cellulose-bio-curatives-for-topical-treatment-of-cutaneous-leishmaniasis
#17
Fabiana S Celes, Eliane Trovatti, Ricardo Khouri, Johan Van Weyenbergh, Sidney J L Ribeiro, Valeria M Borges, Hernane S Barud, Camila I de Oliveira
The treatment of leishmaniasis still relies on drugs with potentially serious adverse effects. Herein, we tested a topical formulation of bacterial cellulose (BC) membranes containing Diethyldithiocarbamate (DETC), a superoxide dismutase 1 inhibitor. Leishmania-infected macrophages exposed to BC-DETC resulted in parasite killing, without pronounced toxic effects to host cells. This outcome was associated with lower SOD1 activity and higher production of superoxide and cytokine mediators. Topical application of BC-DETC significantly decreased lesion size, parasite load and the inflammatory response at the infection site, as well as the production of both IFN-γ and TNF...
December 6, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27916918/subchronic-toxicities-of-hz1006-a-hydroxamate-based-histone-deacetylase-inhibitor-in-beagle-dogs-and-sprague-dawley-rats
#18
Xiaofang Zhang, Xiaodong Zhang, Bojun Yuan, Lijun Ren, Tianbao Zhang, Guocai Lu
Histone deacetylase inhibitors (HDACIs), such as vorinostat and panobinostat, have been shown to have active effects on many hematologic malignancies, including multiple myeloma and cutaneous T-cell lymphoma. Hydroxamate-based (Hb) HDACIs have very good toxicity profiles and are currently being tested in phases I and II clinical trials with promising results in selected neoplasms, such as bladder carcinoma. One of the Hb-HDACIs, HZ1006, has been demonstrated to be a promising drug for clinical use. The aim of our study was to determine the possible target of toxicity and to identify a non-toxic dose of HZ1006 for clinical use...
November 30, 2016: International Journal of Environmental Research and Public Health
https://www.readbyqxmd.com/read/27898459/characterization-of-the-adverse-effects-induced-by-acetaminophen-and-non-steroidal-anti-inflammatory-drugs-based-on-the-analysis-of-the-japanese-adverse-drug-event-report-database
#19
Junko Nagai, Yoshihiro Uesawa, Ryotaro Shimamura, Hajime Kagaya
OBJECTIVES: Acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs) are antipyretic analgesics with established adverse effects; however, only a few studies have compared their adverse effects simultaneously. We aimed to compare the adverse effects of these medications to confirm the respective frequencies of both rare and major adverse effects. METHODS: We used a high-quality database for spontaneous adverse drug event reporting in Japan. Data were extracted regarding the adverse effects of acetaminophen and NSAIDs to compare the tendency of the appearance of those adverse effects between the drugs...
November 24, 2016: Clinical Journal of Pain
https://www.readbyqxmd.com/read/27885401/-cutaneous-side-effects-of-targeted-cancer-drugs
#20
REVIEW
J Below, B Homey, P A Gerber
In the past decades many new drugs were approved for the treatment of cancer and have been established as essential parts of various therapeutic regimens. In particular targeted therapies and immune checkpoint inhibitors that aim at specific carcinogenic signaling pathways or modulate the tumor-immune response have revolutionized cancer therapy. Despite their targeted actions, these drugs may lead to diverse adverse reactions. In particular, cutaneous toxicities represent a serious threat to patients' quality of life and may lead to dose reduction or therapy cessation...
November 24, 2016: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
keyword
keyword
109299
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"